A Real‐World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B‐Cell Lymphoma
L. Elizabeth Budde, Adam J. Olszewski, Bei Hu, Nikesh N. Shah, Connie Lee Batlevi, Shen Yin, Iris To, Michael C. Wei, Martine Joanna Kallemeijn, Lisa Musick, Linda Lundberg, Natasha Shamas, Mark Dixon, Navdeep Pal, Ashwini Shewade, Jason WestinABSTRACT
Introduction
Data for the use of rituximab, gemcitabine, and oxaliplatin (R‐GemOx) for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) in the United States are limited. This retrospective observational study characterizes R‐GemOx treatment patterns and outcomes among patients with R/R LBCL from the nationwide, longitudinal Flatiron Health electronic health record‐derived database comprising patient‐level data primarily from US community oncology practices.
Methods
Patients diagnosed with LBCL who initiated treatment with R‐GemOx in the second or later line of therapy between 2011 and 2023, were included. Patient characteristics, treatment patterns, and efficacy outcomes were assessed.
Results
Of 281 patients, most (66.2%) were treated at community centers. Overall response rate was 45.4% (95% confidence interval [CI]: 38.1–52.9); complete response (CR) rate was 22.2% (95% CI: 16.4–28.8). Median progression‐free and overall survival (OS) were 2.8 months (95% CI: 2.6–3.7) and 12.7 months (95% CI: 10.6–17.1), respectively. In patients who received R‐GemOx in the second line, the CR rate was higher and the median OS was longer versus those who received it in later lines (CR rate, 26.3% vs. 17.4%; median OS, 19.6 vs. 10.0 months, respectively).
Conclusion
These data offer a real‐world benchmark for patterns of use and outcomes of R‐GemOx in patients with R/R LBCL in the United States.
Trial Registration : The authors have confirmed clinical trial registration is not needed for this submission.